The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparing impact of treatment before or after surgery in patients with stage II-IIIb resectable non-small cell lung cancer (NSCLC; Alliance A082304-SWOG S2402).
 
Raid Aljumaily
Research Funding - Abbvie (Inst); Alliance Foundation Trials (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Baxalta (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Huntsman Cancer Institute (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Syneos Health (Inst); Tesaro (Inst)
 
Sumithra Mandrekar
Consulting or Advisory Role - Flatiron Health; Harbinger Oncology, Inc
Other Relationship - Beigene
 
Yingqi Zhao
No Relationships to Disclose
 
Linda Martin
Honoraria - AstraZeneca; Genentech
Consulting or Advisory Role - AstraZeneca; Genentech; On Target Laboratories
Speakers' Bureau - Bristol-Meyers Squibb; Johnson and Johnson
 
David Kozono
Consulting or Advisory Role - Genentech
 
Shauna Hillman
No Relationships to Disclose
 
Anne Chiang
Consulting or Advisory Role - Abbvie; Abbvie; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BMS; Boehringer Ingelheim; Catalyst Pharmaceuticals; Daichi; Flatiron Health; Fosun Pharma; Genentech; Genentech; Genentech; Genentech/Roche; Janssen Oncology; Jazz Pharmaceuticals; Jazz Pharmaceuticals; regeneron; Sanofi/Regeneron; Zai Lab
Research Funding - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Millennium; OncoMed; Onyx; Stem CentRx; Zai Lab
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech/Roche
 
Raymond Osarogiagbon
Employment - Baptist Memorial Healthcare Corporation/Baptist Cancer Center
Stock and Other Ownership Interests - BridgeBio Pharma; Gilead Sciences; Immunocore; Lilly; Pfizer
Honoraria - AstraZeneca; GE Healthcare; MEDIAN Technologies
Consulting or Advisory Role - American Cancer Society; AstraZeneca; Triptych Health Partners
Patents, Royalties, Other Intellectual Property - 2 US and 1 China patents for lymph node specimen collection kit and method of pathologic evaluation.
Travel, Accommodations, Expenses - American Cancer Society; GE Healthcare; MEDIAN Technologies
Other Relationship - Oncobox
 
Tom Stinchcombe
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Coherus Biosciences; Gilead Sciences; Janssen Oncology; Pfizer; Takeda
Research Funding - Boehringer Ingelheim (Inst); Mirati Therapeutics (Inst); Nuvalent, Inc. (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Pfizer
Other Relationship - Genentech; GlaxoSmithKline; Merck; Seagen
 
Jhanelle Gray
Honoraria - AstraZeneca; Blueprint Medicies; Daiichi Sankyo, Inc; EMD Serono/Merck; Flatiron Health; Gilead Sciences; Gilead Sciences; IDEOlogy Health; Janssen Scientific Affairs; Jazz Pharmaceuticals; Loxo; Merck; Merck; Novartis; OncoCyte; Pfizer; Regeneron; Spectrum ODAC; Takeda; Triptych Health Partners
Consulting or Advisory Role - Abbvie; AstraZeneca; Blueprint Meicines; Daiichi Sankyo/UCB Japan; EMD Serono-Merck KGaA; Flatiron Health; Gilead Sciences; IDEOlogy Health; Janssen Scientific Affairs; Jazz Pharmaceuticals; Loxo; Merck; Novartis; OncoCyte Biotechnology Company; Pfizer; Regeneron; Spectrum Pharmaceuticals; Takeda; Triptych Health Partners
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Services (Inst); Lilly (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Novartis (Inst); Panbela Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Abbvie; OncoCyte; Spectrum Pharmaceuticals
 
Daniel Morgensztern
Stock and Other Ownership Interests - Abbott Laboratories; Bristol-Myers Squibb/Medarex
Consulting or Advisory Role - Abbvie; Arcus Biosciences; Bayer; Bristol-Myers Squibb/Medarex; G1 Therapeutics; Johnson & Johnson/Janssen; Lilly Medical; Mirati Therapeutics; Natera; Tubulis GmbH
Research Funding - Abbvie (Inst); Altum Pharmaceuticals (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Baxter (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EpicentRx (Inst); Genprex (Inst); Heat Biologics (Inst); Hybercell (Inst); ImmunityBio (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); NeoImmuneTech (Inst); Pfizer (Inst); Roche (Inst); Surface Oncology (Inst); Y-mAbs Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Genprex